Genolution

Genolution Operating Cash Flow

The Operating Cash Flow of Genolution (225220.KQ) as of Nov 19, 2026 is -7.01 B KRW. In the previous year, Operating Cash Flow was -1.43 B KRW — a change of 389.39% (lower).

Operating Cash Flow

-7.01 BKRW

YoY

389.39%

Last updated:

Operating Cash Flow of Genolution is 2025 -7.01 B KRW. Operating Cash Flow of Genolution was 2024 -1.43 B KRW. It decreases by 389.39% lower compared to the previous year.

The Genolution Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
147.49 M KRW
Jan 1, 2019
-80.58 M KRW
Jan 1, 2020
45.97 B KRW
Jan 1, 2021
25.73 B KRW
Jan 1, 2022
13.55 B KRW
Jan 1, 2023
-1.14 B KRW
Jan 1, 2024
-1.43 B KRW
Jan 1, 2025
-7.01 B KRW
The Genolution Operating Cash Flow history
YEAROperating Cash FlowYoY
-7.01 BKRW+389.39%
-1.43 BKRW+26.17%
-1.14 BKRW-108.38%
13.55 BKRW-47.34%
25.73 BKRW-44.02%
45.97 BKRW-57,148.92%
-80.58 MKRW-154.64%
147.49 MKRW-79.43%
717.13 MKRW-2,755.94%
-27.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Operating Cash Flow of Genolution is -7.01 B KRW in 2025.

Operating Cash Flow of Genolution changed from -1.43 B KRW to -7.01 B KRW, representing a 389.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Genolution since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genolution

All Key Metrics — Genolution